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Progress in medicine has been made in the past primarily through the 
clinical experience of physicians and uncontrolled observations. With the 
advent of medical journals, knowledge dissemination and much of medi-
cal progress had been made possible through clinical reports and metic-
ulous observations on cases or series of cases. This was true for many 
medical breakthroughs, including the initial paper by Burrill Crohn, Leon 
Ginzburg and Gordon Oppenheimer, who described their observations 
of a mere 14 surgical patients with ‘regional ileitis’, which later became 
known as Crohn’s disease.1 However in recent decades, the controlled 
clinical trial gained primacy as the holy grail of evidence-based medicine, 
and observational studies similarly became subject to stricter and prefera-
bly comparative statistical methodology in the forms of population-based 
studies, prospective cohorts or retrospective case-control studies. This 
trend, towards comparative and preferably controlled research method-
ology as the prevailing dogma, has led to case reports falling out of favour 
with the medical scientific community touting its potential caveats of 
chance associations and susceptibility to many uncontrolled confounders. 
Coupled with the fact that case reports may create less citation potential, 
which is necessary for a journal impact factor and citation index standing, 
case reports and case series have also found it increasingly difficult to be 
published.2 Indeed most leading gastroenterology journals, JCC included, 
now generally refrain from publishing case reports or small case series.
Does this mean there is no place for the case report anymore? Is 
there still a case for the small case series?
We believe case reports or case series still have important role in 
advancing medical knowledge, one that is often not possible through 
controlled clinical trials or even through population-based studies. 
Clinical trials, population-based epidemiological investigations and 
even large case-control studies can only investigate the designated 
associations they set for themselves, but are rarely useful for recog-
nising a novel association per se. Moreover, certain sub-populations 
are deliberately excluded from clinical trials, making them inapt to 
disclose associations of therapeutic interventions with certain co-mor-
bidities or specific patient characteristics. Thus, rare and often unex-
pected associations are even nowadays first revealed by case report/s.
One such publication significantly impacted on our medical prac-
tice and has saved many lives, by describing a modestly sized case 
series of patients with tuberculosis following anti-TNF therapy,3 
which was spurred by a single case encountered by Professor Joseph 
Keane in his Irish hospital [Keane J, personal communication]. 
Some cases may be so striking so as to correspond to what may be 
dubbed as the ‘parachute rule’, i.e. even a single case of jumping out 
of a plane and landing safely with a parachute is enough evidence 
to make a controlled trial of parachutes redundant. Similarly, some 
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associations are so unlikely, that even a single case report may indi-
cate a genuine need to alter medical practice or to consider novel 
biological phenomenon. Such was the report in JCC several years 
ago of fatal disseminated BCGosis in a newborn who was exposed 
to infliximab in utero,4 implying that these babies may be at risk if 
given live-attenuated vaccines after birth. Of great importance also 
was the report of progressive multi-focal leukoencephalopathy fol-
lowing natalizumab treatment in a single Crohn’s disease patient.5 
When striking enough, a single case report may even indicate a 
previously unrecognised biological process or phenomenon of high 
importance, such as the recently reported case of human neoplasia 
actually caused by invasive transformed cancer cells from a colonis-
ing tapeworm.6 For these and other rare events, the ability of the 
human mind to pick up extremely unique perturbances of knowl-
edge surpasses the ability of statistics to identify them, despite pre-
sent well-designed clinical trials or population-based studies.
However, to enhance the validity of a single case of a rare event, 
accruing even a handful of similar such cases will support the pur-
ported association. With this understanding in mind, the Collaborative 
Open Network For Extremely Rare cases [CONFER] project was 
initiated by the European Crohn’s and Colitis Organization [ECCO] 
in 2012. ECCO CONFER Cases is an initiative to continuously iden-
tify, assemble and report together rare inflammatory bowel disease 
[IBD] cases or rare cases of IBD-associated diseases and complica-
tions of clinical relevance.
The four categories of topics usually covered by the CONFER 
activities are: rare infections, uncommon drug beneficial effects or 
side effects, rare IBD manifestations and infrequent disease associa-
tions [neoplastic, infectious etc.].
By joining forces with the many members and supporters of 
ECCO, a joint report of all similar such cases can result in a case 
series including more significant numbers of patients which will 
advance our knowledge about these uncommon patients, which 
would otherwise be reported as single case reports or not reported 
at all. ECCO CONFER was launched with the realisation that if a 
particular IBD event is so rare as to be encountered only once by one 
out of 100 IBD experts during their career, than joining forces by the 
>3 000 members of ECCO may result in 30 such cases being identi-
fied, to enhance the scientific robustness of the report.
Since its launch, ECCO CONFER has operated according to a 
structured protocol. A call is made once a year through the official 
ECCO website and via email also to all ECCO Members, to pro-
pose CONFERS case projects. Two to four cases are selected by 
the CONFER steering committee once a year, and the proposing 
investigator then acts as the primary investigator and develops his/
her case into a CONFER case project with the steering committee. 
When the title of the CONFER case project is decided, a call is 
subsequently made to all ECCO members inviting those who have 
encountered a similar case to contribute their case to the CONFER 
case series and become co-investigators for the particular project. 
This call is followed by several reminders if needed. All received 
cases are joined into a case series by the primary investigator and 
prepared for publication. So far, three ECCO CONFER projects 
were successfully completed and have already been published in 
JCC: investigating the occurrence of cerebrovascular events in 
patients treated with anti-TNFs; the association of Cogan’s auto-
immune auditory disorder with IBD; and the association of optic 
neuritis with biologic drugs.7–9 A  minority of CONFER projects 
did not find sufficient numbers of cases and it was decided not to 
continue with submission and eventual publication as a CONFER 
project, and to allow the investigator to report his/her interesting 
case independently.
IBD-logy remains a big challenge for all physicians who are active 
clinicians and work with patients and their daily problems. Progress 
in our understanding of this disease aetiology and its therapy relies 
upon well-designed clinical trials and systematic comparative studies. 
However, the clinical importance of clinical observations in individual 
patients should not be underestimated. Medicine is an art in practice 
which is driven by human ethics, philosophy of life, technology and 
experimental data but also by pioneers who had the ability to observe 
and report significant data on individual patients. Uncontrolled obser-
vations of uncommon events can still result in unravelling disease 
aetiology, improving diagnostic strategies and enriching therapeutic 
outcomes. We believe there is still room for educated, careful, uncon-
trolled observations of uncommon clinical events or associations. 
Their rarity and nature call for collaborative reporting efforts span-
ning hundreds of doctors, to yield the best possible evidence.
We believe that ECCO CONFER and other similar initiatives 
have proven and will continue to prove the value and contribution of 
case reports to medical knowledge, even in a medical world reigned 
by group-comparative statistics.
In addition, through this manuscript, we would like also to 







Founding team of ECCO CONFER: Shomron Ben-Horin [Israel], Eugeni 
Domènech [Spain], Kostas Katsanos [Greece], Jean-François Rahier [Belgium]. The 
ECCO CONFER Steering Committee members would like to thank all ECCO 
Governing Board and ECCO Scientific Committee members for supporting the 
ECCO CONFER project, the ECCO Office personnel and all ECCO CONFER 
project collaborators for their valuable contribution to the success of the project.
References
 1. Crohn B, Ginzburg L, Oppenheimer G. Regional ileitis: a pathologic and 
clinical entity. JAMA 1932;99:1323–9.
 2. Kidd M, Hubbard C. Introducing Journal of Medical Case Reports. J Med 
Case Reports 2007;1:1.
 3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with inflixi-
mab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 
2001;345:1098–104.
 4. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal 
case of disseminated BCG infection in an infant born to a mother taking 
infliximab for Crohn’s disease. J Crohns Colitis 2010; 4:603–5.
 5. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoen-
cephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 
2005;353:362–8.
 6. Muehlenbachs A, Bhatnagar J, Agudelo CA, et al. Malignant transformation 
of Hymenolepis nana in a human host. N Engl J Med 2015;373:1845–52.
 7. Vavricka SR, Greuter T, Scharl M, et al.; for the ECCO CONFER investi-
gators. Cogan’s syndrome in patients with inflammatory bowel disease–a 
case series. J Crohns Colitis 2015;9:886–90.
 8. Alexandre B, Vandermeeren Y, Dewit O, et  al.; for the ECCO CONFER 
investigators. Optic neuritis associated or not with TNF antagonists in 
patients with inflammatory bowel disease. J Crohns Colitis 2016;10:541–8.
 9. Karmiris K, Bossuyt P, Sorrentino D, et al.; for the ECCO CONFER investiga-
tors. Cerebrovascular events in inflammatory bowel disease patients treated 
with anti-tumour necrosis factor alpha agents. J Crohns Colitis 2015;9:382–9.
2 K. H. Katsanos et al.
 by guest on N
ovem
ber 8, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
